People on HIV drugs have ‘substantial’ Alzheimer’s protection: study
May 12, 2025People taking drugs for HIV and hepatitis B are less likely to develop Alzheimer’s disease, according to a new study. UVA Health investigators now would like clinical trials to examine the potential of the HIV medications as a means to prevent Alzheimer’s disease.
REINFORCE Resource Guide
April 18, 2024This Resource Guide was developed as part of the HealthHIV REINFORCE initiative supporting five healthcare organizations to increase their retention and re-engagement in HIV care rates. These sites, situated around the country, ranged from large multi-site hospitals and health centers to small community-based organizations.
Inflamm-aging: Effects of Chronic Inflammation with HIV
February 5, 2024Advances in Antiretroviral therapy (ART) allow people with HIV to live longer with fewer medications. Join us as Dr. Peter Hunt details the connection between chronic inflammation and HIV infection and discusses care considerations and emerging research.
Monocytes in HIV and SIV Infection and Aging: Implications for Inflamm-Aging and Accelerated Aging
February 17, 2022With ART and the extended lifespan of PLWH, HIV comorbidities also include aging—most likely due to accelerated aging—as well as cardiovascular, neurocognitive disorders, lung and kidney disease, and malignancies. The broad evidence suggests that HIV with ART is associated with accentuated aging and that the age-related comorbidities occur earlier, due in part to chronic immune activation, co-infections, and possibly the effects of ART alone.
Senotherapeutics for HIV and aging
March 1, 2021Senescence is a hallmark of aging-related diseases that is characterized by stable cell cycle arrest and chronic inflammation. Chronic HIV-1 infection predisposes patients to aging-related illnesses and is similarly marked by a senescence-like phenotype. A better understanding of the role of HIV-1 in aging will inform the development of therapeutics aimed at eliminating senescent cells that drive accelerated physiologic aging.
A continuum of HIV care describing mortality and loss to follow-up: a longitudinal cohort study
June 4, 2018A cross-sectional study assessed how effective it was for those on HIV meds to not transmit to others, along with how high the loss to follow-up was in various HIV programs. They found that there was a high loss of follow-up in HIV care programs, but it highlighted the need for intervention as well as an increase in rates of viral suppression.
